Generic Drug Pricing Transparency Could Reduce Spending, Study Says
Executive Summary
Every $1 reduction in the average reimbursement for a generic prescription would reduce US healthcare spending by $4bn, according to a study from Brookings, which concludes more generic drug pricing information should be selectively available to third-party payers.
You may also be interested in...
Generic Manufacturers Try To Up Their Game As US Pressure Persists
With US generic drug price erosion running at double digits, 2017 is expected to be a challenging year for the generic drug sector. Manufacturers are looking increasingly to complex generics, injectables and biosimilars as an offset, but it's unclear if wins in those areas will be enough to bridge the growth divide.
Pharma And Intermediaries Split Money Spent On Drugs, Study Shows
For every $100 spent at retail pharmacies, $41 accrues to the manufacturer and $41 accrues to intermediaries in the distribution system, according to a new study on US prescription drug spending, though drug manufacturers hold onto more profit.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.